journal
MENU ▼
Read by QxMD icon Read
search

Lancet Diabetes & Endocrinology

journal
https://www.readbyqxmd.com/read/28330649/effect-of-sacubitril-valsartan-versus-enalapril-on-glycaemic-control-in-patients-with-heart-failure-and-diabetes-a-post-hoc-analysis-from-the-paradigm-hf-trial
#1
Jelena P Seferovic, Brian Claggett, Sara B Seidelmann, Ellen W Seely, Milton Packer, Michael R Zile, Jean L Rouleau, Karl Swedberg, Martin Lefkowitz, Victor C Shi, Akshay S Desai, John J V McMurray, Scott D Solomon
BACKGROUND: Diabetes is an independent risk factor for heart failure progression. Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and improves peripheral insulin sensitivity in obese hypertensive patients. We aimed to investigate the effect of sacubitril/valsartan versus enalapril on HbA1c and time to first-time initiation of insulin or oral antihyperglycaemic drugs in patients with diabetes and HFrEF...
March 17, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28330648/glycaemic-control-in-heart-failure-a-paradigm-shift-for-patients-with-concomitant-diabetes
#2
Gregory Giamouzis, Javed Butler
No abstract text is available yet for this article.
March 17, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28320585/what-research-is-needed-to-address-the-co-epidemics-of-hiv-and-cardiometabolic-disease-in-sub-saharan-africa
#3
Pascal Geldsetzer, Jennifer Manne-Goehler, Till Bärnighausen, Justine Ina Davies
No abstract text is available yet for this article.
March 17, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28330591/essential-medicines-and-access-to-insulin
#4
LETTER
Geoff Gill, John S Yudkin, Solomon Tesfaye, Maximilian de Courten, Edwin Gale, Ayesha Motala, Kaushik Ramaiya, Nigel Unwin, Sarah Wild
No abstract text is available yet for this article.
March 15, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28291677/correction-to-lancet-diabetes-endocrinol-2017-published-online-jan-23-http-dx-doi-org-10-1016-s2213-8587-17-30014-1
#5
(no author information available yet)
No abstract text is available yet for this article.
March 10, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28259647/does-fetal-exposure-to-vitamin-d-programme-childhood-bone-mass
#6
Christopher S Kovacs
No abstract text is available yet for this article.
March 1, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28259646/25-hydroxyvitamin-d-concentrations-during-fetal-life-and-bone-health-in-children-aged-6-years-a-population-based-prospective-cohort-study
#7
Audry H Garcia, Nicole S Erler, Vincent W V Jaddoe, Henning Tiemeier, Edith H van den Hooven, Oscar H Franco, Fernando Rivadeneira, Trudy Voortman
BACKGROUND: 25-hydroxyvitamin D (25[OH]D) concentrations during fetal life might have long-lasting effects on skeletal development, but results from previous studies are inconsistent. We investigated the associations of maternal and fetal 25(OH)D concentrations with childhood bone health. METHODS: In a prospective multiethnic population-based cohort study, embedded within the Generation R Study (Rotterdam, Netherlands), pregnant women living in the study area with an expected delivery date between April 1, 2002, and Jan 1, 2006, were eligible for participation in the study at our research centre in the Erasmus MC-Sophia Children's Hospital...
March 1, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28258842/gestational-diabetes-in-the-first-trimester-is-early-testing-justified
#8
Arianne N Sweeting, Glynis P Ross, Jon Hyett, Jencia Wong
No abstract text is available yet for this article.
February 28, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28237790/changing-ethical-and-legal-norms-in-the-management-of-differences-of-sex-development
#9
Maayan Sudai
No abstract text is available yet for this article.
February 22, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28237789/microvascular-complications-after-metabolic-surgery
#10
George K Dimitriadis, Harpal S Randeva, Alexander D Miras
No abstract text is available yet for this article.
February 22, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28215937/long-term-treatment-with-evolocumab-added-to-conventional-drug-therapy-with-or-without-apheresis-in-patients-with-homozygous-familial-hypercholesterolaemia-an-interim-subset-analysis-of-the-open-label-taussig-study
#11
Frederick J Raal, G Kees Hovingh, Dirk Blom, Raul D Santos, Mariko Harada-Shiba, Eric Bruckert, Patrick Couture, Handrean Soran, Gerald F Watts, Christopher Kurtz, Narimon Honarpour, Lihua Tang, Sree Kasichayanula, Scott M Wasserman, Evan A Stein
BACKGROUND: Homozygous familial hypercholesterolaemia is a genetic disorder characterised by substantially raised LDL cholesterol, reduced LDL receptor function, xanthomas, and cardiovascular disease before age 20 years. Conventional therapy is with statins, ezetimibe, and apheresis. We aimed to assess the long-term safety and efficacy of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab in a subset of patients with homozygous familial hypercholesterolaemia enrolled in an open-label, non-randomised phase 3 trial...
February 16, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28215938/limitations-of-cholesterol-lowering-with-pcsk9-inhibitors
#12
Gilbert Thompson
No abstract text is available yet for this article.
February 15, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28169174/blood-pressure-goals-in-type-2-diabetes-assessing-the-evidence
#13
Peter M Nilsson, Sverre E Kjeldsen
No abstract text is available yet for this article.
February 3, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28159506/elimination-of-iodine-deficiency-disorders-from-the-americas-a-public-health-triumph
#14
Eduardo A Pretell, Elizabeth N Pearce, Sergio A Moreno, Omar Dary, Roland Kupka, Małgorzata Gizak, Jonathan Gorstein, Ruben Grajeda, Michael B Zimmermann
No abstract text is available yet for this article.
January 31, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28131656/integration-of-recent-evidence-into-management-of-patients-with-atherosclerotic-cardiovascular-disease-and-type-2-diabetes
#15
REVIEW
Eberhard Standl, Oliver Schnell, Darren K McGuire, Antonio Ceriello, Lars Rydén
Cardiovascular outcome trials of antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabetes who have, or who are at high risk of, atherosclerotic cardiovascular disease have provided new evidence that has substantially affected the management of cardiovascular risk in these patients. On the basis of proven cardiovascular and renal benefit, the antihyperglycaemic drugs empagliflozin, liraglutide, and semaglutide-the latter being under review for approval by the US Food and Drug Administration and the European Medicines Agency-should be preferentially used as second-line treatments in these patient populations, typically in addition to metformin...
January 25, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28126459/exercise-management-in-type-1-diabetes-a-consensus-statement
#16
REVIEW
Michael C Riddell, Ian W Gallen, Carmel E Smart, Craig E Taplin, Peter Adolfsson, Alistair N Lumb, Aaron Kowalski, Remi Rabasa-Lhoret, Rory J McCrimmon, Carin Hume, Francesca Annan, Paul A Fournier, Claudia Graham, Bruce Bode, Pietro Galassetti, Timothy W Jones, Iñigo San Millán, Tim Heise, Anne L Peters, Andreas Petz, Lori M Laffel
Type 1 diabetes is a challenging condition to manage for various physiological and behavioural reasons. Regular exercise is important, but management of different forms of physical activity is particularly difficult for both the individual with type 1 diabetes and the health-care provider. People with type 1 diabetes tend to be at least as inactive as the general population, with a large percentage of individuals not maintaining a healthy body mass nor achieving the minimum amount of moderate to vigorous aerobic activity per week...
January 24, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28108304/non-surgical-treatment-of-diabetic-foot-osteomyelitis
#17
Mesut Mutluoglu, Benjamin A Lipsky
No abstract text is available yet for this article.
January 17, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28110912/semaglutide-a-promising-new-glucagon-like-peptide-1-receptor-agonist
#18
André J Scheen
No abstract text is available yet for this article.
January 16, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28110911/efficacy-and-safety-of-once-weekly-semaglutide-monotherapy-versus-placebo-in-patients-with-type-2-diabetes-sustain-1-a-double-blind-randomised-placebo-controlled-parallel-group-multinational-multicentre-phase-3a-trial
#19
Christopher Sorli, Shin-Ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Stephen C Bain
BACKGROUND: Despite a broad range of pharmacological options for the treatment of type 2 diabetes, optimum glycaemic control remains challenging for many patients and new therapies are necessary. Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 development for type 2 diabetes. We assessed the efficacy, safety, and tolerability of semaglutide monotherapy, compared with placebo, in treatment-naive patients with type 2 diabetes who had insufficient glycaemic control with diet and exercise alone...
January 16, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28094137/the-artificial-pancreas-ready-for-prime-time
#20
J Hans DeVries
No abstract text is available yet for this article.
January 13, 2017: Lancet Diabetes & Endocrinology
journal
journal
47944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"